Tap - XTP

에 대한 최신 뉴스 Molson Coors Beverage (NYSE:TAP) 주식

Molson Coors Beverage

Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.

News

Movers

주요 주류 생산업체와 유통업체들의 주식은 미국 공중보건국장인 비벡 머시(Vivek Murthy)가 알코올 소비와 관련된 암 위험 증가에 대해 경고한 후 금요일 급락했다. 

금요일 미국 주류 주식이 하락 마감: 무슨 일이?

Analyst Color

Equities

Upgrades

Price Target

Reiteration

Analyst Ratings

Trading Ideas

General

골드만삭스(Goldman Sachs)의 분석가 본니 헤르조그(Bonnie Herzog)는 최근 베버리지 바이트(Beverage Bytes)의 설문조사에서 맥주 유통업체들로부터 얻은 피드백을 바탕으로 몰슨 쿠어스 베버리지(NYSE:TAP)와 콘스텔레이션 브랜드(Constellation Brands Inc) (NYSE:STZ)에 대한 판단을 좀 더 긍정적이고, 보스톤 비어 컴퍼니(NYSE:SAM)에 대한 판단을 부정적으로 바꿨다.

골드만삭스는 몰슨 쿠어스와 컨스텔레이션 브랜드에 대해 더 긍정적 견해: 이유는?

Molson Coors Beverage Company Class B Common Stock

Molson Coors Beverage Co

Molson Coors Beverage Company Class A Common Stock

TAI PING CARPETS INTL by Tai Ping Carpets International

TRIPUTRA AGRO PERSADA TBK by TRIPUTRA AGRO PERSADA TBK PT

PT Triputra Agro Persada Tbk

Tapinator Inc

Tap Resources Inc

Shares of major alcohol producers and distributors declined sharply Friday following a warning issued by U.S. Surgeon General Vivek Murthy about the increased cancer risks <a href="https://www.benzinga.com/government/regulations/25/01/42787400/alcohol-increases-cancer-risk-surgeon-general-warns">associated with alcohol consumption.</a>
What To Know: Murthy&#8217;s advisory emphasized the need for updated health warning labels to reflect mounting evidence of alcohol&#8217;s connection to cancer. These labels have not been revised since 1988. The advisory also called for reassessing recommended alcohol consumption limits, highlighting alcohol's role as the third-leading preventable cause of cancer in the United States, behind tobacco and obesity.
Murthy&#8217;s statement drew attention to alcohol&#8217;s association with at least seven types of cancer, including breast, liver and colorectal cancers. He pointed out that alcohol consumption contributes to approximately 100,000 cancer cases and 20,000 deaths annually in the United States. The announcement highlighted that only 45% of American adults are aware of the cancer risks posed by alcohol.
Stocks of leading alcohol companies reacted negatively to the news. 
Molson Coors Beverage Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) saw its shares drop by 3.72%, while Boston Beer Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) shares fell 4.26%. Anheuser-Busch InBev Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>)&#8217;s stock declined by 1.84% and Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) saw a 1.5% decrease. Diageo Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>) stock also traded lower, falling 3.15%. Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>), the maker of Jack Daniel&#8217;s whiskey, experienced a 2.58% decline.
The Surgeon General's advisory reignited discussions about public health measures and the potential for new regulations requiring updated warning labels on alcohol products. 
Price Action: Molson Coors shares were down 3.25% at $55.27, Boston Beer shares were down 3% at $292.60 and Anheuser-Busch shares were down 1.85% at $49 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
Image Via Shutterstock.

Alcohol Stocks Are Falling Today: What's Going On?

Molson Coors Beverage Co Class B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) shares are trading lower by 2.7% to $55.69 during Friday&#8217;s session. Shares of <a href="https://www.benzinga.com/money/best-alcohol-stocks">alcohol stocks</a> are trading lower after U.S. Surgeon General Murthy issued an advisory warning alcohol consumption could raise cancer risk.
What To Know: The announcement heightens public awareness of the health dangers linked to alcohol consumption and <a href="https://www.benzinga.com/government/regulations/25/01/42787400/alcohol-consumption-increases-cancer-risk-surgeon-general-warns-calls-for-changes-in-warning-labels">could lead to stricter regulations</a>, such as updated warning labels and lower recommended drinking limits. 
As a company reliant on beer sales, Molson Coors may face reduced consumer demand if these warnings deter drinking, especially among health-conscious demographics. Additionally, potential regulatory changes could increase costs related to compliance, marketing and product labeling. 
Since beer represents a significant share of Molson Coors&#8217; revenue, heightened scrutiny of alcohol's role in cancer could disproportionately impact its financial outlook compared to that of diversified alcohol producers. Investor uncertainty about future sales and increased regulatory risks likely contributed to the stock's sharp decline.
Read Also: <a href="https://www.benzinga.com/25/01/42787508/biden-blocks-149b-takeover-of-us-steel-shares-plunge">Biden Blocks $14.9B US Steel Takeover, Shares Plunge</a>
<h2 class="wp-block-heading">How To Buy TAP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Molson Coors Beverage&#8217;s case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TAP has a 52-week high of $69.18 and a 52-week low of $49.19.

What's Going On With Molson Coors Beverage Shares?

WIIM

Fomento Economico Mexicano S.A.B. De C.V.

Shares of alcohol stocks are trading lower after US Surgeon General Murthy issued an advisory warning alcohol consumption could raise cancer risk.

Surgeon General Vivek H. Murthy issued an advisory Friday warning about the cancer risks associated with alcohol consumption and calling for updates to health warning labels that haven't been revised since 1988. Murthy also stressed the need to reassess recommended alcohol limits, citing mounting evidence of its role in <a href="https://www.benzinga.com/general/health-care">cancer development</a>. The advisory sent alcohol stocks plunging across the board in Friday morning trading.
"Higher alcohol consumption increases alcohol-related cancer risk, yet only 45% of American adults are aware that consuming alcohol increases their risk of developing cancer," Murthy&nbsp;wrote on X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">NEW: Today, I'm releasing a Surgeon General's Advisory on the causal link between alcohol consumption and increased cancer risk. Alcohol is the 3rd leading preventable cause of cancer in the U.S., contributing to about 100,000 cancer cases and 20,000 cancer deaths each year. <a href="https://t.co/sKTlPAZlFw">pic.twitter.com/sKTlPAZlFw</a>
&mdash; Dr. Vivek Murthy, U.S. Surgeon General (@Surgeon_General) <a href="https://twitter.com/Surgeon_General/status/1875150669935685855?ref_src=twsrc%5Etfw">January 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases and 20,000 deaths annually in the United States," Murthy stated. He added that alcohol consumption ranks as the third-leading preventable cause of cancer in the U.S., trailing only tobacco and obesity. 
Murthy's advisory, <a href="https://www.washingtonpost.com/health/2025/01/03/alcohol-cancer-warning-surgeon-general/">noted</a> the Washington Post, pointed to a direct association between alcohol consumption and at least seven types of cancer, including breast, liver and colorectal cancers. The Post pointed out that 16.4% of annual breast cancer cases are attributed to alcohol and that any mandatory changes to the health warning labels would need to be approved by the new Congress coming in under President-elect Donald Trump.
<h2 class="wp-block-heading">Alcohol Makers, Distributor Stocks React</h2>
Stocks of major alcohol companies fell sharply following the announcement, according to Benzinga Pro. 
Brown-Forman Corp. (NYSE: <a href="https://www.benzinga.com/quote/BF-B">BF-B</a>) producer of Jack Daniel's whiskey, is down 2.58%. Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), distributor of Corona beers and Mondavi wines, declined by 1.5%. Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) is down 1.84%, Molson Coors Beverage Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) is down by 3.37%% while the Boston Beer Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>), maker of Sam Adams, plunged 4.26%. Diageo plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) is trading down 3.15%. 
Photo: <a href="https://www.thecrimson.com/writer/1219214/Courtesy%20of%20U.S.%20Department%20of%20Health%20and%20Human%20Services__/">Courtesy of U.S. Department of Health and Human Services</a>

Government

Regulations

Health Care

Markets

BF/B

Molson Coors, Diageo, Boston Beer Tumble As Surgeon General Warns 'Alcohol Consumption Increases' Cancer Risk

As 2025 dawns, a cultural revolution is blooming across the United States, with cannabis emerging as a transformative force among all sectors of society. Once relegated to the shadows of illegality and stigma, cannabis now enjoys a prominent role in healthcare, <a href="https://www.benzinga.com/cannabis">industry and social life.</a>
For the first time ever, the number of Americans who consume cannabis on a nearly daily basis <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">surpassed the number of people</a> who drink that often, a shift some 40 years in the making as marijuana is now legal in some form in nearly half of all U.S. states.
<h2 class="wp-block-heading">A Decades-Long Transformation</h2>
A recent Bloomberg Intelligence survey confirms this shift, revealing that 44% of Americans now favor cannabis over alcohol, a jump from 33% just a year ago, <a href="https://www.marijuanamoment.net/analysts-see-sudden-spike-in-use-of-marijuana-as-an-alcohol-alternative/">reported</a> Marijuana Moment. This dramatic rise signals an evolution in societal attitudes, driven by wellness consciousness and a desire for alternatives to alcohol's negative health and social impacts.
Younger generations, particularly Millennials and Gen Z, are at the forefront of this change, although Baby Boomers <a href="https://www.benzinga.com/markets/cannabis/23/08/33583433/baby-boomers-turning-to-weed-en-masse-say-it-improves-memory-and-mood-doctors-agree-cnn-series-e">are also joining the trend</a>, attracted by marijuana&#8217;s therapeutic benefits.
Cannabis-derived products like CBD-infused beverages, topicals and edibles also dominate wellness markets, appealing to people of all ages.
The journey to mainstream acceptance has also been decades in the making, supported by <a href="https://www.benzinga.com/markets/cannabis/24/06/39368875/cannabis-found-less-harmful-than-alcohol-in-new-study-where-is-the-demand-heading-investor-marke">numerous studies confirming</a> that cannabis is far less harmful than alcohol. Cannabis legalization does not lead to increased fatalities on the road, according to a <a href="https://qz.com/advisor/auto-insurance/has-marijuana-legalization-made-roads-less-safe" target="_blank" rel="noreferrer noopener">study</a> using data sourced from the <a href="https://injuryfacts.nsc.org/state-data/motor-vehicle-deaths-by-state/" target="_blank" rel="noreferrer noopener">National Safety Council</a>.
Read Also: <a href="https://www.benzinga.com/24/12/42690082/trump-is-first-republican-president-with-a-pathway-to-cannabis-reform-says-former-adviser">Trump Is First &#8216;Republican President&#8217; With A Pathway To Cannabis Reform, Says Former Adviser</a>
<h2 class="wp-block-heading">Economic Ripples And Industry Adaptation</h2>
The economic impact of cannabis is undeniable. The U.S. legal cannabis market exceeded $30 billion in 2023, with <a href="https://www.benzinga.com/news/retail-sales/24/11/42193387/federal-policy-could-add-3-billion-to-cannabis-industry-on-track-to-reach-55-billion-by-2030">projections suggesting</a> it could reach $55 billion by 2030. States like California, Colorado and New York are leading the charge, fueling <a href="https://www.benzinga.com/markets/cannabis/24/04/38183087/cannabis-industry-has-created-nearly-half-a-million-full-time-jobs-new-report-reveals-which-stat">job creation</a> and innovation. Ancillary industries, ranging from packaging to marketing, are thriving. Even alcohol companies are pivoting, investing in cannabis-infused beverages to remain competitive.
Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) recently launched a series of products across its craft beer and beverage brands. The Canadian cannabis giant has been <a href="https://www.benzinga.com/markets/cannabis/23/09/34579077/tilrays-beer-business-expands-nationally-starting-in-this-state" target="_blank" rel="noreferrer noopener">buying beer brands</a> as part of its <a href="https://www.benzinga.com/markets/cannabis/23/08/33612189/tilray-acquires-8-beer-brands-from-struggling-bud-light-parent-anheuser-busch-heres-what-it-mean">ongoing strategy</a> to establish its presence in the U.S. One of its recent moves valued at $2 million was the purchase of <a href="https://www.benzinga.com/markets/cannabis/24/08/40365052/billion-dollar-cannabis-firm-buys-a-brewery-four-actually-in-canadas-backyard">four craft breweries</a> from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>).
<h2 class="wp-block-heading">Social And Policy Implications</h2>
Federal legalization remains contentious as the outgoing Biden administration failed to reschedule cannabis and remove it from the&nbsp;<a href="https://www.benzinga.com/topic/controlled-substances-act" target="_blank" rel="noreferrer noopener">Controlled Substances Act</a>&nbsp;(CSA), which was <a href="https://www.benzinga.com/markets/cannabis/24/11/41752800/kamala-harris-promises-to-legalize-recreational-marijuana-in-groundbreaking-instagram-post" target="_blank" rel="noreferrer noopener">promised to voters</a>&nbsp;on a regular basis.
Now cannabis advocates are waiting to see what President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a> will do on that score. He too <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">has said</a> he'd reschedule cannabis.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42710061/cannabis-reform-2024-the-year-of-all-talk-and-no-action">Cannabis Reform 2024: The Year Of All Talk And No Action</a></li>
</ul>
Photo: MexChriss/Shutterstock.com

Cannabis

Politics

Legal

TLRY

Cannabis In 2025: Inside America's Social, Economic, Wellness Transformation

B of A Securities analyst Bryan Spillane upgrades Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from Neutral to Buy and raises the price target from $57 to $70.

B of A Securities Upgrades Molson Coors Beverage to Buy, Raises Price Target to $70

Following sluggishness during the summer months, trends in the U.S. beer market are showing signs of improvement, according to Needham.
There is a great deal of uncertainty around potential tariffs, which will likely create a near-term overhang, beer is "better positioned than distilled spirits" in the current environment, says <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6304db77e4a8c500019458fb/gerald-pascarelli">analyst </a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6304db77e4a8c500019458fb/gerald-pascarelli">Gerald Pascarelli</a>.
The analyst initiated coverage of these two better stocks:
<h1 class="wp-block-heading">Constellation Brands</h1>
Pascarelli initiated coverage of Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy rating and a price target of $280.
While tariffs will remain a concern, Constellation Brands recently gained market share, which should enable the company to meet its revised guidance for fiscal 2025, Pascarelli said in the initiation note.
Constellation Brands is "the best company" in the Beverage space, the analyst stated. Within beer, the company continues to generate "the best revenue growth and operating margins," he added.
The stock is likely to trade higher, "given their historical and consistent relative levels of outperformance, combined with improved capital allocation and corporate governance," the analyst further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Molson Coors Beverage</h1>
In a separate note, Pascarelli initiated coverage of Molson Coors Beverage Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Buy rating and a price target of $72.
The brewing contract with Pabst coming to an end positions Molson Coors Beverage to improve its volumes, the analyst said.
There is upside to the current Street estimates for the company, which imply growth significantly below the company's long-term targets, Pascarelli stated. Molson Coors Beverage should be able to meet its growth targets "through incremental cost savings along with optionality to deploy cash towards share buybacks," he further wrote.
Price Action
At the time of publication Friday:
<ul>
<li>STZ: Shares of Constellation Brands had risen by 0.78% to $241.36</li>
<li>TAP: Molson Coors Beverage's stock had climbed 0.59% to $61.31.</li>
</ul>
Read More: • <a href="https://www.benzinga.com/news/global/24/11/42220682/trump-tariffs-on-mexico-could-affect-beer-why-your-modelo-corona-could-cost-more-next-year">Trump Tariffs On Mexico Could Affect Beer: Why Your Modelo, Corona Could Cost More Next Year</a>
Photos: Shutterstock

Long Ideas

Initiation

Trump's Beer Tariffs Cloud Sector: Molson Coors Is Well Positioned, But This Is The 'Best Company In The Beverage Space,' Says Analyst

Needham analyst Gerald Pascarelli initiates coverage on Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Buy rating and announces Price Target of $72.

Needham Initiates Coverage On Molson Coors Beverage with Buy Rating, Announces Price Target of $72

Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Molson Coors Beverage, revealing an average target of $61.0, a high estimate of $74.00, and a low estimate of $51.00. Marking an increase of 12.96%, the current average surpasses the previous average price target of $54.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732536034_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Molson Coors Beverage by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Grundy</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Vivien Azer</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molson Coors Beverage. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Molson Coors Beverage compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Molson Coors Beverage's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Molson Coors Beverage's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molson Coors Beverage analyst ratings.</a>
<h2>Unveiling the Story Behind Molson Coors Beverage</h2>
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
<h3>Unraveling the Financial Story of Molson Coors Beverage</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Molson Coors Beverage faced challenges, resulting in a decline of approximately -7.75% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Molson Coors Beverage's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 6.57%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Molson Coors Beverage's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.51%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Molson Coors Beverage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.74%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Molson Coors Beverage's debt-to-equity ratio stands notably higher than the industry average, reaching 0.47. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Molson Coors Beverage

Exane BNP Paribas analyst Kevin Grundy initiates coverage on Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral rating and announces Price Target of $64.

Exane BNP Paribas Initiates Coverage On Molson Coors Beverage with Neutral Rating, Announces Price Target of $64

Barclays analyst Lauren Lieberman maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Underweight and raises the price target from $49 to $51.

Barclays Maintains Underweight on Molson Coors Beverage, Raises Price Target to $51

Molson Coors Beverage shares are trading higher after Wells Fargo upgraded the stock from Underweight to Overweight and raised its price target from $52 to $74.

Wells Fargo analyst Chris Carey upgrades Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from Underweight to Overweight and raises the price target from $52 to $74.

Wells Fargo Upgrades Molson Coors Beverage to Overweight, Raises Price Target to $74

Donald Trump&#8216;s 2024 presidential election win put several sectors in the spotlight, <a href="https://www.benzinga.com/topic/alcohol">including alcohol stocks.</a>
What Happened: Some people watched the outcome of <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">election night</a> on television from their home. Others likely scrolled along with social media on their phone. Some attended watch parties with friends and families, similar to a Super Bowl party or one for <a href="https://www.benzinga.com/top-stories/24/08/40610039/are-nvidia-earnings-wall-streets-super-bowl-super-bulls-arrange-watch-parties-in-new-york-city">Nvidia's quarterly earnings.</a> 
Regardless of who voters wanted to win — Trump or Kamala Harris — they may have bought more alcohol for Election Day this year, at least in New York, with liquor stores reporting a busy day.
One liquor store <a href="https://nypost.com/2024/11/06/us-news/nyc-liquor-stores-were-crazy-busy-on-election-night-workers-say-weve-been-spending-hours-just-restocking/">told </a>the New York Post they were three to four times busier than a regular weekday on Election Day with heavy sales coming in the early afternoon and around 5 p.m. ET. An employee from Brooklyn's Juice Box liquor store told the Post there was also a noticeable trend from many customers.
"People were buying sparkling wine and a bottle of liquor for both (outcomes)," the employee said.
Employees from other New York stores noticed the same trend. Customers were either buying one type of alcohol for a happy outcome or one for a negative outcome.
"I have no idea if people will be drowning their sorrows or celebrating," the Juice Box employee added.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While it is only one day of the year, Election Day 2024 could provide a short bump for alcohol stocks like Diageo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) and Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>). Beer stocks like Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>), Boston Beer Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) and Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) may have also benefitted from Election Day.
Alcohol may be a coping or celebratory item for Election Day in the U.S., but in India the country <a href="https://timesofindia.indiatimes.com/world/us/us-election-2024-does-america-have-dry-days-like-india-during-election-season/articleshow/114945854.cms">has </a>dry days of no alcohol around their elections with residents unable to drink for 48 hours before the vote, on election day or as the vote is being totaled.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41817245/will-trump-be-sentenced-in-hush-money-trial-or-will-his-criminal-problems-go-away">Will Trump Be Sentenced In Hush Money Trial Or Will His &#8216;Criminal Problems Go Away&#8217;?</a></li>
</ul>
Image: Shutterstock

Alcohol Stocks To Get A Boost From 2024 Election? Busy Liquor Stores Say Voters 'Drowning Their Sorrows Or Celebrating'

Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) reported third-quarter adjusted earnings per share of $1.80, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41801425/molson-coors-beverage-company-reports-2024-third-quarter-results" rel="noreferrer noopener">beating the street view of $1.67.</a>
Quarterly sales of $3.04 billion missed the analyst consensus of $3.13 billion. Net sales decreased 7.8%, driven by lower financial volumes, partially offset by favorable price and sales mix.
Financial volumes dropped 12.3%, mainly due to lower shipments, including reduced contract brewing volumes in the Americas. Brand volumes fell 4.4%, with a 5.4% decline in the Americas and a 1.8% decrease in EMEA &amp; APAC.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41813356/elon-musks-net-worth-soars-by-26-5-billion-in-single-day-after-tesla-stock-surges-post-trump-vic" rel="noreferrer noopener">Elon Musk&#8217;s Net Worth Soars By $26.5 Billion In Single Day After Tesla Stock Surges Post-Trump Victory</a>
Net sales benefited from a 4.5% positive price and sales mix impact, driven by higher net pricing and a favorable sales mix, including the impact of reduced contract brewing volumes in the U.S.
Total debt as of September 30 was $6.2 billion, and cash and equivalents totaled $1.02 billion, resulting in a net debt of $5.219 billion.
In a separate release, Molson Coors said it is acquiring a majority stake in ZOA, the energy brand co-founded by Dwayne Johnson, and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41801128/molson-coors-beverage-company-takes-majority-stake-in-zoa-energy" rel="noreferrer noopener">will now lead its marketing and sales efforts</a>. The company expects this move to drive significant growth for ZOA.
&#8220;We&#8217;re building a winning portfolio that offers consumers choices across a wide range of occasions, and non-alc is a key part of that strategy,&#8221; said Molson Coors Chief Commercial Officer Michelle St. Jacques.
Molson Coors and ZOA first struck a partnership when the brand launched in 2021, and Molson Coors increased its stake in ZOA last September while also assuming a presence on ZOA&#8217;s Board of Directors.
Outlook: Molson Coors now expects net sales to decline by about 1% in 2024 compared to 2023 on a constant currency basis. This is a revision from their previous forecast of a low single-digit increase, due to <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">weaker performance in the U.S. beer industry during the peak selling season.</a>
The company now expects its 2024 underlying diluted earnings per share to be at the high end of the prior outlook range&nbsp;of a mid-single-digit increase compared to 2023.
Price Action: TAP shares are trading higher by 0.68% to $56.91 at last check Thursday.
Photo via Shutterstock
Read also:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different" target="_blank" rel="noreferrer noopener">How Did S&amp;P 500 Sectors Perform During Trump&#8217;s First Term? Could This Time Be Different?</a></li>
</ul>

Earnings

Guidance

Molson Coors' Q3 Mixed Bag: Earnings Win, Sales Drop, And Bold Bet On Non-Alcoholic With Dwayne 'The Rock' Johnson's ZOA

Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.67 by 7.78 percent. The company reported quarterly sales of $3.04 billion which missed the analyst consensus estimate of $3.13 billion by 2.84 percent. This is a 7.73 percent decrease over sales of $3.30 billion the same period last year.

Earnings Beats

Earnings Misses

Molson Coors Beverage Q3 2024 Adj EPS $1.80 Beats $1.67 Estimate, Sales $3.04B Miss $3.13B Estimate

Molson Coors Beverage Takes Majority Stake In ZOA Energy; Terms Not Disclosed

Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) remains a cautious investment, according to Zuanic &amp; Associates, despite its solid balance sheet and diverse global assets. With a "Neutral" rating, Zuanic views Tilray as a long-term player in the cannabis sector, though short-term uncertainties cloud its outlook.
Tilray's international presence is expanding, notably in <a href="https://www.benzinga.com/topic/germany-cannabis">Germany</a>, where sales have grown 50%. Yet, headwinds persist, including high operating expenses, rising share count and ongoing market share losses in Canada where Tilray has opted against aggressive discounting in certain product categories.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">U.S. Beverage Expansion Shows Potential</h3>
In the U.S., Tilray has bolstered its beverage portfolio with <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">craft beer brands </a>acquired from Molson Coors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>), positioning itself to gain ground in the non-alcoholic hemp drink market &#8211; a segment showing explosive growth potential.
Still, <a href="https://www.benzinga.com/markets/cannabis/24/10/41273594/tilray-reports-200m-q1-net-revenue-up-13-yoy-as-net-loss-improves">Tilray's revenue</a>, at $200 million for the August quarter, trails its $950 million target for FY25, casting doubt on near-term growth momentum.
<h3 class="wp-block-heading">Rising Costs And Dilution</h3>
Tilray's operating expenses remain a point of concern, with Selling, General &amp; Administrative (SGA) costs reaching 34% of sales in the first quarter of FY25 &#8211; an increase from 31% in FY24. This rise in cash SGA expenses has contributed to a 300 basis point drop in Tilray's adjusted EBITDA margin.
Additionally, Tilray's share count has grown significantly, increasing from 657 million in FY23 to 903.3 million by October 2024. While this higher share count bolsters liquidity, it also affects per-share revenue metrics.
Despite the dilution, Tilray's revenue per share has remained stable, reflecting accretive growth from recent acquisitions. However, the increased equity base will require the company to continue driving organic growth to justify valuation metrics and support long-term investor confidence.
Read Also: EXCLUSIVE:<a href="https://www.benzinga.com/markets/cannabis/24/10/41502695/exclusive-tilray-ceo-irwin-simon-on-why-us-cannabis-rescheduling-wont-change-a-billion-dollar-pl"> Tilray CEO Irwin Simon On Why US Cannabis Rescheduling Won&#8217;t Change A Billion-Dollar Play</a>
<h3 class="wp-block-heading">Valuation Premium And Investor Outlook</h3>
Valued at an estimated $1.67 billion, Tilray trades at a 1.7x EV/sales multiple, with its cannabis segment trading at a premium of 4x, well above industry norms.
While Tilray's liquidity and extensive market reach make it a formidable <a href="https://www.benzinga.com/markets/cannabis/24/09/40919186/cannabis-giant-tilray-expands-medical-marijuana-portfolio-with-redecan-launch-in-australia">global contender</a>, Zuanic advises investors to await clearer evidence of sustainable growth across international markets and gains in operational efficiency.
<h3 class="wp-block-heading">Path Ahead: Strategic Global Expansion</h3>
Tilray's journey hinges on its ability to capitalize on international cannabis expansion, reinvigorate its U.S. brands, and improve financial performance. For now, Zuanic &amp; Associates suggests that potential investors stay on the sidelines, with Tilray's future resting on a steady, strategic push through emerging global markets.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41599546/canadas-cannabis-market-goes-cold-pot-prices-hit-bottom-why-top-producers-are-losin"> Canada&#8217;s Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground</a>

Retail Sales

Beyond Beer, Tilray's $1.67 Billion Market Play: Is This Cannabis Giant Still A Smart Buy?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>TD Cowen raised Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) price target from $133 to $149. TD Cowen analyst Bill Katz maintained a Hold rating. Blackstone shares closed at $169.73 on Thursday. <a href="https://www.benzinga.com/quote/bx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan boosted the price target for Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from $57 to $60. JP Morgan analyst Andrea Teixeira maintained a Neutral rating. Molson Coors Beverage shares closed at $56.05 on Thursday. <a href="https://www.benzinga.com/quote/tap/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for Webster Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) from $60 to $63. Barclays analyst Jared Shaw maintained an Overweight rating. Webster Financial shares closed at $54.25 on Thursday. <a href="https://www.benzinga.com/quote/wbs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) price target from $190 to $216. Goldman Sachs analyst Ryan Nash maintained a Neutral rating. M&amp;T Bank shares settled at $198.87 on Thursday. <a href="https://www.benzinga.com/quote/mtb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital cut ManpowerGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) price target from $87 to $71. BMO Capital analyst Jeffrey Silber maintained a Market Perform rating. Synchrony Financial shares closed at $67.05 on Thursday. <a href="https://www.benzinga.com/quote/man/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Great Southern Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSBC#NASDAQ">GSBC</a>) price target from $64 to $62. Piper Sandler analyst Andrew Liesch maintained a Neutral rating. Great Southern Bancorp shares closed at $58.64 on Thursday. <a href="https://www.benzinga.com/quote/gsbc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised the price target for BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) from $2.7 to $2.8. Canaccord Genuity analyst Kingsley Crane maintained a Hold rating. BlackBerry shares settled at $2.58 on Thursday. <a href="https://www.benzinga.com/quote/bb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein raised Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $625 to $780. Bernstein analyst Laurent Yoon maintained a Market Perform rating. Netflix shares closed at $687.65 on Thursday. <a href="https://www.benzinga.com/quote/nflx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS increased the price target for Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) from $102 to $114. UBS analyst Lloyd Walmsley maintained a Buy rating. Uber shares closed at $79.90 on Thursday. <a href="https://www.benzinga.com/quote/uber/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) price target from $165 to $190. B of A Securities analyst Vivek Arya maintained a Buy rating. NVIDIA shares closed at $136.93 on Thursday. <a href="https://www.benzinga.com/quote/nvda/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NVDA stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18113114/image-167-1024x517.png" alt="" class="wp-image-603007" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18113114/image-167-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18113114/image-167-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18113114/image-167-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18113114/image-167.png 1317w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

GSBC

NFLX

NVDA

UBER

NVIDIA To Rally Around 39%? Here Are 10 Top Analyst Forecasts For Friday

JP Morgan analyst Andrea Teixeira maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and raises the price target from $57 to $60.

JP Morgan Maintains Neutral on Molson Coors Beverage, Raises Price Target to $60

The Surgeon General pushes for cancer warning labels for alcoholic drinks

Shares of drink makers fell on Friday morning after the U.S. surgeon general issued an advisory on alcohol on cancer risk, outlining a direct link ...

Drink makers drop as Surgeon General proposes cancer warning on alcohol

Beer and spirits investors have a chance to fade the Surgeon General

Molson Coors ($TAP), and other alcohol stocks, have lost their fizz on news that the U.S. Surgeon General wants to place new labels on beer, wine, ...

Molson Coors (TAP) Stock Loses Fizz as U.S. Surgeon General Calls for New Warning Label on Alcohol

Trending stocks as Wall Street steps into first days of 2025 with cautiousness

2024 winners and losers in consumer staples: Walmart and Kellanova top charts

Alcohol companies could face a challenge with younger consumers after Surgeon General warning

Trump lambasts report of pared down tariff plans (update)

Anheuser-Busch InBev inks deal to produce beer for Pabst Blue Ribbon

Citi says avoid these stocks in '25; SA Quant Ratings says not so fast

AAPL

ABEV

ALTO

ANFGF

ARRY

ASAN

BRBR

BRFS

CABGY

CALM

CELH

CENX

COST

CRNC

CSIQ

CSTM

CVNA

DGEAF

DLTR

DVCMY

DVDCF

ENPH

FLNC

FSLR

FSTA

GLCNF

GLNCY

HEINY

IART

INGR

IVPAF

JJSF

KALU

LANC

LCID

MAXN

MGPI

MNST

MTCH

NISTF

NMRA

NOVA

NPSCY

NXPI

PDRDF

PLUG

POST

PRNDY

RGTI

RIVN

SCCO

SEDG

SHLS

SMPL

SNDL

SNDR

SOFI

SOUN

STLD

TCBI

TECK

TSLA

ULCC

VINE

VWESQ

WERN

Press Releases

Molson Coors Beverage Company Announces Regular Quarterly Dividend

Molson Coors Beverage Company Reports 2024 Second Quarter Results

Tilray Brands to Acquire Four Craft Beer Breweries from Molson Coors Beverage Company

Tilray Brands Completes Acquisition of Craft Beer Brands and Breweries from Molson Coors Beverage Company

Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company

Molson Coors Beverage Company to Webcast 2024 Third Quarter Earnings Conference Call

Molson Coors Beverage Company Takes Majority Stake in ZOA Energy

Molson Coors Beverage Company Reports 2024 Third Quarter Results

Molson Coors Beverage Company to Webcast 2024 Fourth Quarter and Full Year Earnings Conference Call

TSX:TLRY

TSX:TPX

TSX:TPX.A

TSX:TPX.B

Ambev S.A. American Depositary Shares (Each representing 1 Common Share)

Ambev

Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

Anheuser-Busch InBev

Compania Cervecerias Unidas, S.A. Common Stock

United Breweries Co

Boston Beer Company, Inc. (The) Common Stock

Boston Beer Co

B of A Securities

Needham

Exane BNP Paribas

Barclays

Wells Fargo

Molson Coors Brewing

주요 주류 생산업체와 유통업체들의 주식은 미국 공중보건국장인 비벡 머시(Vivek Murthy)가 <a href="https://www.benzinga.com/government/regulations/25/01/42787400/alcohol-increases-cancer-risk-surgeon-general-warns" target="_blank" rel="noopener" data-google-interstitial="false">알코올 소비와 관련된</a> 암 위험 증가에 대해 경고한 후 금요일 급락했다.
알아야 할 사항: 머시의 권고는 알코올과 암의 연관성에 대한 증거가 증가하고 있음을 반영하여 건강 경고 라벨을 업데이트할 필요성을 강조했습니다. 이 라벨은 1988년 이후로 개정되지 않았다. 또한 권고된 알코올 소비 한도의 재평가를 촉구하며, 알코올이 미국에서 담배와 비만에 이어 세 번째로 예방 가능한 암 발생 원인임을 강조했다.
머시의 성명은 알코올이 유방암, 간암 및 대장암 등 적어도 7종의 암과 연관되어 있음을 주목하게 했다. 그는 알코올 소비가 매년 약 100,000건의 암 사례와 20,000명의 사망을 초래한다고 지적했다. 또한 미국 성인 중 45%만이 알코올이 암 위험을 증가시킨다는 사실을 알고 있다.
주요 주류 회사들의 주식은 이 뉴스에 부정적으로 반응했다.
주가 움직임: 몰슨 쿠어스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)의 주식은 3.37% 하락 마감했으며, 보스턴 비어 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>)의 주식은 3.83% 하락 마감했다. 앤하이저부시 인베브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>)의 주식은 2.14% 하락 마감했고, 컨스텔레이션 브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)는 0.29% 하락 마감했다. 디아지오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>)의 주식도 3.76% 하락 마감했다. 잭 다니엘스 위스키 제조사인 브라운 포먼(NYSE:<a href="https://www.benzinga.com/quote/BF-B" target="_blank" rel="noopener">BF/B</a>)은 2.53% 하락 마감했다.
공중보건국장의 권고는 공공 건강 조치와 알코올 제품에 대한 경고 라벨 업데이트를 요구하는 새로운 규제의 가능성에 대한 논의를 재점화했다.
이미지 출처: Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

골드만삭스(Goldman Sachs)의 분석가 본니 헤르조그(Bonnie Herzog)는 최근 베버리지 바이트(Beverage Bytes)의 설문조사에서 맥주 유통업체들로부터 얻은 피드백을 바탕으로 몰슨 쿠어스 베버리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)와 콘스텔레이션 브랜드(Constellation Brands Inc) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)에 대한 판단을 좀 더 긍정적이고, 보스톤 비어 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>)에 대한 판단을 부정적으로 바꿨다.
이 분석가는 몰슨 쿠어스 베버리지의 주식평가를 <a href="https://www.benzinga.com/quote/TAP/analyst-ratings" target="_blank" rel="noreferrer noopener">중립 에서 매수로</a> 상향 조정했으며, 목표 주가도 66달러에서 75달러로 상향 조정했다.
헤르조그는 유통업체들이 TAP가 봄 선반 재설정의 큰 승자가 될 것으로 예상하고, 평균적으로 한 자릿수 중반의 선반 공간 비율을 점진적으로 확보할 것으로 기대한다는 점을 고려하면 긍정적인 위험/보상을 본다.
더 많은 유통업체들이 밀러 라이트(Miller Lite) 및 쿠어스 라이트(Coors Light)의 점유율 강화를 보고 있으며, 거의 80%의 유통업체들가 해당 브랜드가 점유율을 유지할 것으로 기대하고 있다고 그가 말했다.
이 분석가는 유통업체들의 78%가 3월에 TAP 브랜드의 재고를 더 많이 보유하고 있었으며 이는 TAP가 봄 재설정을 앞두고 1분기에 예상보다 더 많이 출하했을 수 있음을 시사한다.
그는 미주 지역의 출하량/고갈 성장에 대한 개선된 전망을 반영하여 TAP의 1분기 실적이 양호한 것으로 예상하고 있다.
이 분석가는 TAP의 시장 점유율 순풍이 현재 시장이 평가하는 것보다 더 지속 가능하다는 것이 입증됨에 따라 주식이 더 높게 재평가될 것으로 예상한다.
이 분석가는 콘스텔레이션 브랜드 주식에 대해 4월 11일에 발표될 4분기 실적을 앞두고 290달러의 목표주가와 <a href="https://www.benzinga.com/quote/STZ/analyst-ratings" target="_blank" rel="noreferrer noopener">매수 평가</a>를 재확인했다.
그는 STZ의 맥주 거래량 트렌드가 견고하며, 이번 봄에 추가로 선반과 쿨러 공간을 확보하는 데 가장 큰 수혜자가 될 것으로 예상되기 때문에 잠재적인 매출과 순익 선점이 가능할 것으로 보고 있다.
이 분석가의 긍정적인 견해는 강력한 소비자 수요, 유리한 인구 통계적 트렌드, 강력하고 명확한 브랜드 포지셔닝으로 인해 모델로(Modelo)에 대한 장기적인 성장 여정을 지지한다.
그는 STZ의 강력한 혁신으로 인해 역사적으로 30%였던 생산량 증가율이 향후 5년 동안 최대 40%까지 증가할 것으로 예상한다.
이 분석가는 모델로가 이끄는 핵심 맥주 브랜드를 통해 매력적인 성장을 이룰 수 있을 만큼 STZ의 사업에서 충분한 모멘텀을 계속해서 확인하고 있다. STZ는 그가 선호하는 최고의 주식 중 하나이다.
그는 보스톤 비어의 주식에 대한 평가를 <a href="https://www.benzinga.com/quote/SAM/analyst-ratings" target="_blank" rel="noreferrer noopener">매도로</a> 재확인했으며, 목표 주가는 257달러에서 250달러로 하향 조정했다.
이 분석가에 따르면 유통업체들은 새로운 경쟁업체들이 하드 티(hard tea) 카테고리에 넘쳐나면서 지난 몇 달 동안 트위스티드 티(Twisted Tea)의 모멘텀이 둔화되기 시작했다고 보고했다.
트위스티드 티(Twisted Tea)에 대한 낙관적인 전망에도 불구하고, 트위스티드 티가 트룰리(Truly)의 손실을 상쇄할 만큼 충분한 가치가 있는지에 대한 불확실성을 고려할 때, SAM의 리스크보상은 여전히 부정적인 쪽으로 기울어져 있다는 점을 이 분석가는 지적했다.
그는 유통사들이 SAM 제품의 재고를 계속해서 줄이고 있으며 봄 초기화 기간 동안 선반/쿨러 공간을 더 적게 할당할 것으로 기대한다.
따라서 이 분석가는 1분기의 회계연도 24/24/25년간의 주당 순이익 예측치를 각각 -$0.28/-$0.58/-$0.46, 즉 $0.11/$9.72/$12.63으로 하향 조정했다.
그는 지속적인 톱라인 턴어라운드 스토리의 징후가 더 많이 나타날 때까지 단기적으로 주식에 대한 부정적인 위험/보상이 더 많다고 본다.
주가 움직임: 화요일, SAM 주식은 1.92% 하락한 291.31달러에 마감했다.
사진 제공: 셔터스톡

Comments

Molson Coors Beverage

뉴스

에 대한 최신 뉴스 Molson Coors Beverage (NYSE:TAP) 주식

금요일, 1월 03, 2025

수요일, 4월 10, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌